Keith Murphy's Biography

Keith Murphy, CEO, Organovo

Mr. Murphy has more than 20 years of experience in biotechnology, including serving in Product Strategy and Director of Process Development roles at Amgen. He is a co-founder of Organovo and has been responsible for all company operations since 2007. His ten years at Amgen included four years as Global Operations Leader for the largest development program in Amgen’s history, Phase 3 osteoporosis/bone cancer drug denosumab. At Amgen, he also worked to develop several other novel formulation and device products. Prior to Amgen, he played a central role at Alkermes, Inc. on the development team for their first approved product, Nutropin (hGH) Depot. He holds a B.S. in chemical engineering from the Massachusetts Institute of Technology and is an alumnus of the UCLA Anderson School of Management.